PMID- 34681263
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211026
IS  - 1424-8247 (Print)
IS  - 1424-8247 (Electronic)
IS  - 1424-8247 (Linking)
VI  - 14
IP  - 10
DP  - 2021 Oct 12
TI  - Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors 
      from Evidence to Clinical Practice: A Systematic Review.
LID - 10.3390/ph14101039 [doi]
LID - 1039
AB  - Neuroendocrine neoplasms (NENs) are relatively rare and complex tumors that can 
      be sporadic or hereditary, as in the context of multiple endocrine neoplasia type 
      1 (MEN1) where patients display a 70% lifelong risk of developing a pancreatic 
      NENs (pNENs). To date, specific personalized treatment for pNENs in patients with 
      MEN1 are lacking. The aim of this study was to systematically analyze the 
      efficacy and safety of somatostatin analogue (SSA) treatment in patients affected 
      by MEN1-related pNENs. We performed a systematic review of the literature, 
      searching for peer-reviewed articles on SSA (octreotide or lanreotide) treatment 
      in MEN1 associated with pNENs. We selected 20 studies with a pooled population of 
      105 MEN1 patients with pNENs. Females were 58.5%, median age was 44 years 
      (18-73). TNM stage at diagnosis was stage I-II in 84.8% and stage IV in 15.2%. 
      The overall response rate (SD+PR+CR) was achieved in 88.3% of cases, with stable 
      disease in 75.6% and objective response in 12.7% of patients. The safety profile 
      was favorable with both SSA agents. SSAs appear to be an effective and safe 
      treatment option for MEN1-related pNEN, either at localized or advanced stages.
FAU - La Salvia, Anna
AU  - La Salvia A
AUID- ORCID: 0000-0002-5020-8657
AD  - Department of Oncology, 12 de Octubre University Hospital, 28045 Madrid, Spain.
FAU - Sesti, Franz
AU  - Sesti F
AUID- ORCID: 0000-0003-3850-627X
AD  - Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, 
      Italy.
FAU - Grinzato, Chiara
AU  - Grinzato C
AD  - Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, 
      Italy.
FAU - Mazzilli, Rossella
AU  - Mazzilli R
AD  - Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza 
      University of Rome, 00189 Rome, Italy.
FAU - Tarsitano, Maria Grazia
AU  - Tarsitano MG
AD  - Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, 
      Italy.
FAU - Giannetta, Elisa
AU  - Giannetta E
AD  - Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, 
      Italy.
FAU - Faggiano, Antongiulio
AU  - Faggiano A
AUID- ORCID: 0000-0002-9324-3946
AD  - Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, 
      Italy.
AD  - Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza 
      University of Rome, 00189 Rome, Italy.
LA  - eng
GR  - PRIN2017Z3N3YC/PRIN/
PT  - Journal Article
PT  - Review
DEP - 20211012
PL  - Switzerland
TA  - Pharmaceuticals (Basel)
JT  - Pharmaceuticals (Basel, Switzerland)
JID - 101238453
PMC - PMC8538402
OTO - NOTNLM
OT  - MEN-1
OT  - efficacy
OT  - pancreatic neuroendocrine tumors
OT  - personalized treatment
OT  - safety
OT  - somatostatin analogues
COIS- The authors declare no conflict of interest.
EDAT- 2021/10/24 06:00
MHDA- 2021/10/24 06:01
PMCR- 2021/10/12
CRDT- 2021/10/23 01:06
PHST- 2021/08/31 00:00 [received]
PHST- 2021/10/06 00:00 [revised]
PHST- 2021/10/08 00:00 [accepted]
PHST- 2021/10/23 01:06 [entrez]
PHST- 2021/10/24 06:00 [pubmed]
PHST- 2021/10/24 06:01 [medline]
PHST- 2021/10/12 00:00 [pmc-release]
AID - ph14101039 [pii]
AID - pharmaceuticals-14-01039 [pii]
AID - 10.3390/ph14101039 [doi]
PST - epublish
SO  - Pharmaceuticals (Basel). 2021 Oct 12;14(10):1039. doi: 10.3390/ph14101039.